Dongwha Pharm.Co.,Ltd completed the acquisition of 53.3% stake in MEDYSSEY Co.,Ltd from Jongwook Jang, Min-kyung Jang, Ho-jeong Kim, Ji-won Jang and Seon-ok Kim.
September 23, 2020
Share
Dongwha Pharm.Co.,Ltd (KOSE:A000020) agreed to acquire a 53.3% stake in MEDYSSEY Co.,Ltd (XKON:A200580) from Jongwook Jang, Min-kyung Jang, Ho-jeong Kim, Ji-won Jang and Seon-ok Kim for KRW 19.6 billion on July 24, 2020. As part of the transaction, Dongwha Pharm.Co.,Ltd will acquire 1,598,358 shares from Jongwook Jang, 62,000 shares from Seon-ok Kim, 16,420 shares from Min-kyung Jang, 16,420 shares from Ji-won Jang and 325,000 shares from Ho-jeong Kim in MEDYSSEY Co.,Ltd. Board of Directors of MEDYSSEY Co.,Ltd resolved the transaction and it is expected to close on September 24, 2020.
Dongwha Pharm.Co.,Ltd (KOSE:A000020) completed the acquisition of 53.3% stake in MEDYSSEY Co.,Ltd (XKON:A200580) from Jongwook Jang, Min-kyung Jang, Ho-jeong Kim, Ji-won Jang and Seon-ok Kim on September 24, 2020.
MEDYSSEY CO.,LTD is a Korea-based company mainly engaged in the manufacture of orthopedic spinal implants. The Company's product portfolio consists of spinal fixation systems that used for lumbar and lumbosacral degenerative pathologies, semi-rigid systems, posterior lumbar interbody fusion (PLIF) cages, PLIF expandable cages, porous cages, transforaminal lumbar interbody fusion (TLIF) cages, cervical plates, cervical cages, high tibial osteotomy systems, pectus bars, omega fixation systems, inter-spinous devices and others.
Dongwha Pharm.Co.,Ltd completed the acquisition of 53.3% stake in MEDYSSEY Co.,Ltd from Jongwook Jang, Min-kyung Jang, Ho-jeong Kim, Ji-won Jang and Seon-ok Kim.
MEDYSSEY CO.,LTD 
